0001628280-23-036462.txt : 20231102
0001628280-23-036462.hdr.sgml : 20231102
20231102165823
ACCESSION NUMBER: 0001628280-23-036462
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231031
FILED AS OF DATE: 20231102
DATE AS OF CHANGE: 20231102
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ragan Paula
CENTRAL INDEX KEY: 0001769914
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38295
FILM NUMBER: 231373378
MAIL ADDRESS:
STREET 1: C/O X4 PHARMACEUTICALS, INC.
STREET 2: 955 MASSACHUSETTS AVE., 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: X4 Pharmaceuticals, Inc
CENTRAL INDEX KEY: 0001501697
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 273181608
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 61 NORTH BEACON STREET
STREET 2: 4TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02134
BUSINESS PHONE: 857-529-8300
MAIL ADDRESS:
STREET 1: 61 NORTH BEACON STREET
STREET 2: 4TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02134
FORMER COMPANY:
FORMER CONFORMED NAME: Arsanis, Inc.
DATE OF NAME CHANGE: 20100920
4
1
wk-form4_1698958692.xml
FORM 4
X0508
4
2023-10-31
0
0001501697
X4 Pharmaceuticals, Inc
XFOR
0001769914
Ragan Paula
C/O X4 PHARMACEUTICALS, INC.
61 NORTH BEACON STREET, 4TH FLOOR
BOSTON
MA
02134
1
1
0
0
President and CEO
0
Common Stock
2023-10-31
4
A
0
532081
0
A
1075878
D
Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurs upon FDA acceptance of a new drug application for mavorixafor.
/s/ Adam S. Mostafa, attorney-in-fact
2023-11-02